Sunday, August 16, 2026 Never miss a recall or a rule change Go Pro · $20/mo →
Inside MedSpa
FDA Recall & Compliance Alerts for Medspa Owners
InjectablesHugel Posts Record H1 on Toxin Surge—Overseas Growth AcceleratestodayMarketHugel Posts Record H1 Revenue on Overseas Toxin Surge3 days agoDevices & TechApyx: GLP-1 Boom Is Fueling Renuvion DemandtodayMarketMedytox Q2 Sales Up 11%, Operating Profit Down 25%3 days agoInjectablesGalderma Wins EU Nod for Restylane ShaypeyesterdayBusiness & M&AEstablishment Labs Raises 2026 Revenue Guidance2 days agoDevices & TechMerz Ultherapy PRIME Clears FDA for Knee Skin LaxityyesterdayBusiness & M&ABeauty Health Q2 Earnings: Device Demand Steady2 days agoInjectablesHugel Debuts Thechaum Signature with Reduced CrosslinkeryesterdayDevices & TechAlma Launches TitaniumLift™ Multi-Depth RF Protocol2 days agoInjectablesGLP-1 Boom Exposed Filler Limitations—Here's WhyyesterdayInjectablesGalderma Chief: Start GLP-1 Patients on Skin Care First2 days ago
Markets & Filings

S-1 / IPO Filing

The SEC registration a company files to go public, revealing financials and risks ahead of its IPO.

Also known as: Form S-1, Registration Statement

What it is
An S-1 is the registration statement a private company files with the SEC to sell shares to the public. It discloses financials, risk factors, and use of proceeds. Its filing marks the start of the IPO process, subject to SEC review.
What it does
An S-1 filing signals a coming supply of new stock and reveals a company's economics for the first time, moving comparable public peers and sector sentiment. IPO pricing and lockup expirations are downstream catalysts. Government shutdowns can stall SEC review.
The evidence
High-profile S-1 filings have moved publicly traded peers as investors reprice the sector and anticipate new supply.
Best for
Public comparables in the filer's sector; recent-IPO cohorts.
Pairs well with
8-k, government-shutdown, catalyst
Use cautiously with
A filing is not a completed IPO; deals get pulled or repriced, and peer reactions can reverse.
Cautions
Lockup expirations after the IPO can pressure the new stock and its peers.
General information, not medical advice. Ingredient effects vary by formulation, concentration, and skin. Patch-test new actives and consult a qualified provider before starting prescription ingredients.

More markets & filings

Know what's coming before your patients ask for it.

New actives, device launches, and the FDA calls that change what you can offer — distilled into a two-minute brief, twice a week. Inside MedSpa Pro.

Go Pro · $20/mo
Inside MedSpa Pro

By the time it's news, it's too late.

The rebate cut, the scope-of-practice bill, the competitor opening down the street — it hits your business before the trade press ever covers it. Pro gets you there first: what happened, why it touches your margins, and exactly what to do — at 6 AM, in two minutes.

Go Pro · $20/mo Never miss a recall or a rule change. Cancel anytime.
The twice-a-week intelligence brief Go Pro · $20/mo →